Tarsus Announces Proposed $100.0 Million Underwritten Public Offering of Shares of its Common Stock
31 juil. 2023 16h29 HE
|
Tarsus Pharmaceuticals, Inc
IRVINE, Calif., July 31, 2023 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (Nasdaq: TARS) (the “Company” or “Tarsus”), whose mission is to focus on unmet needs and apply proven science and new...
FDA Approves XDEMVY™ (lotilaner ophthalmic solution) 0.25% for the treatment of Demodex blepharitis
25 juil. 2023 07h00 HE
|
Tarsus Pharmaceuticals, Inc
XDEMVY is the first and only approved therapeutic for Demodex blepharitis, a highly prevalent eyelid disease that impacts approximately 25 million eye care patients in the U.S. XDEMVY targets the...
Tarsus to Host Virtual Investor Webcast Highlighting the Commercialization Strategy, Plans and Progress for TP-03, Its Potential Treatment for Demodex Blepharitis
12 juin 2023 08h30 HE
|
Tarsus Pharmaceuticals, Inc
IRVINE, Calif., June 12, 2023 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize...
Tarsus to Present at the Jefferies Global Healthcare Conference
05 juin 2023 08h30 HE
|
Tarsus Pharmaceuticals, Inc
IRVINE, Calif., June 05, 2023 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize...
Tarsus Reports First Quarter 2023 Financial Results and Recent Business Achievements
09 mai 2023 16h05 HE
|
Tarsus Pharmaceuticals, Inc
Continuing to build market awareness through disease education and deploying commercial leadership in anticipation of TP-03 August 25, 2023 PDUFA Presented health economics data suggesting a...
Tarsus Launches “Don’t Freak Out. Get Checked Out.” Campaign During Healthy Vision Month to Encourage Patients with Demodex Blepharitis to Visit Eye Care Providers
08 mai 2023 08h30 HE
|
Tarsus Pharmaceuticals, Inc
Demodex blepharitis is a highly prevalent, yet often undiagnosed eyelid disease that impacts approximately 25 million eye care patients in the U.S. IRVINE, Calif., May 08, 2023 (GLOBE NEWSWIRE) --...
Tarsus to Participate at the Bank of America 2023 Healthcare Conference
03 mai 2023 16h30 HE
|
Tarsus Pharmaceuticals, Inc
IRVINE, Calif., May 03, 2023 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize...
Tarsus Appoints Jeff Farrow as Chief Financial Officer and Chief Strategy Officer
24 avr. 2023 08h30 HE
|
Tarsus Pharmaceuticals, Inc
IRVINE, Calif., April 24, 2023 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize...
Tarsus Reports Full-Year 2022 Financial Results and Recent Business Achievements
13 mars 2023 16h05 HE
|
Tarsus Pharmaceuticals, Inc
Engaging with more than two-thirds of key optometrists and/or ophthalmologists, and top payers on Demodex blepharitis in anticipation of TP-03 August 25, 2023 PDUFA Completed enrollment of Ersa, a...
Tarsus to Present at Upcoming Investor Conferences
02 mars 2023 16h30 HE
|
Tarsus Pharmaceuticals, Inc
IRVINE, Calif., March 02, 2023 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize...